Evidence map›Paper›PMID 42051541›Full record

ArticleFrontiers in immunology2026

Comparing CD8+ T cell ENV epitopes of two HLA class I alleles associated with different outcomes of HIV-1 infection with broadly neutralizing antibodies epitope targets discovered to date.

Akhil Ramdoyal, Christina A Daniuk, Robert Were Omange, Joshua Kimani, Ma Luo

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Akhil RamdoyalMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Christina A DaniukNational Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB, Canada.
Robert Were OmangeBiomarker Sciences, Gilead Sciences, Foster City, CA, United States.
Joshua KimaniDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.
Ma LuoNational Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HIV vaccine field has swung between humoral-based to cell-mediated approaches; however the consensus has evolved toward the understanding that an induction of both may be important for optimal protection. HLA class I molecules present viral epitopes to initiate CD8+ T cell responses to HIV-infected cells while broadly neutralizing antibodies (bNAbs) primarily target free virions. In this study, we systematically compared HIV-1 ENV CD8+ T cell epitopes restricted by two HLA class I alleles associated with divergent HIV-1 infection outcomes with bNAb epitopes reported to date in the literature. To our knowledge, this represents one of the first attempts of examining and reconciling the targets of cellular and humoral immunity in the context of differing HIV infection outcomes. Among 1820 peptides overlapping HIV-1 clades A and D ENV, A*01:01 (associated with slower HIV-1 acquisition) bound to 20, while B*07:02 (associated with susceptibility) bound to 64. No significant differences in affinity or off-rate were noted between A*01:01 and B*07:02 epitopes, and a higher proportion of A*01:01 epitopes are located within constant ENV regions than B*07:02 epitopes (C:V ratio 3:1 versus 2:1, respectively). Of the epitopes and variants discovered in this study, 7 of 20 (35%) A*01:01 and 11 of 64 (17%) B*07:02 binders overlapped with known bNAb target sites. All CD8+ T cell epitopes overlapping CD4-binding site clusters were also bNAbs targets. Notably, all A*01:01 T cell epitopes overlapping bNAb epitopes were within conserved ENV regions, and all but one involved glycan-dependent bNAb binding. The epitope landscape analysis therefore showed the allele associated with slower HIV-1 infection rates presents a narrower repertoire of ENV CD8

Indexed as

Antibodies, NeutralizingCD8-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusEpitopes, T-LymphocyteHistocompatibility Antigens Class IHIV-1HIV AntibodiesHIV InfectionsAllelesHumansAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopes, T-LymphocyteHistocompatibility Antigens Class IHIV Antibodiesbroadly neutralizing antibodies (bNab)CD8+ T cellsHIV-1 envelope (ENV)HLA-A*01:01HLA-B*07:02immunotherapynatural immunityPumwani cohort

Identifiers

PMID42051541
PMCPMC13111375

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.